Elevated Hematocrit
Current management often responds after hematologic elevation occurs.
A new standard in androgen therapy safety
Redefining Androgen Therapy Through Pharmacokinetic Control
A translational platform designed to reduce therapy-induced erythrocytosis through upstream modulation of androgen exposure dynamics while preserving therapeutic androgen activity.
The Limitation of Current Androgen Therapy
Treatment Interruption
Dose reductions and phlebotomy may compromise therapeutic continuity.
Exposure Dynamics Matter
Peak androgen burden may disproportionately stimulate erythropoietic signaling.
"Erythrocytosis is not simply a dose problem - it may be an exposure-shape problem."
Our platform science
Modulating the Biology of Erythropoiesis
Transient peak androgen exposure can drive erythropoietic signaling through a coordinated network involving EPO stimulation, hepcidin suppression, iron mobilization, and marrow activation, culminating in elevated hematocrit.
Learn More About Our Science
Androgen Therapy
Peak Androgen Burden (Cmax)
EPO Signaling
Hepcidin Suppression
Bone Marrow Activation
Red Blood Cell Production
Hematocrit Elevation
PK Modulation Platform
Reduced Peak Exposure. Preserved Therapeutic Androgen Activity.
The Erythraxis Platform
Absorption Control
Optimize the rate and extent of systemic androgen appearance.
Release Engineering
Design release kinetics that flatten peaks while maintaining exposure.
Metabolic Modulation
Modulate metabolic pathways to shift exposure curves.
First-Pass Optimization
Control oral bioavailability and peak systemic exposure.
Route Selection
Identify routes with favorable PK dynamics for target populations.
Biomarker Integration
Use biomarkers to guide, monitor, and refine therapeutic modulation.
Our development pathway
A Platform Built for Translational Development
From mechanistic modeling to human pilot studies, our program is designed to rigorously evaluate PK modulation strategies and their impact on erythropoietic biology.
Mechanistic Modeling
Define mechanisms and exposure-response relationships.
PK Modulation Screening
Evaluate non-limiting strategies in vitro and in silico.
Candidate Ranking
Rank candidates by PK impact, feasibility, and safety profile.
Human Pilot Studies
Assess PK, biomarkers, and hematologic outcomes.
Advancing the Future of Androgen Therapeutics
For Researchers
Collaborate to expand the science of androgen exposure and erythropoiesis.
Request OverviewFor Strategic Partners
Partner with us to develop the next generation of PK modulation therapies.
Partnership InquiryFor Clinical Collaboration
Work with us to design studies that transform patient outcomes in androgen therapy.
Clinical CollaborationLeadership
Led by Commercial Execution and Clinical Expertise
Erythraxis brings together disciplined operational leadership and frontline genitourinary medicine experience to advance a translational androgen therapy platform.
Founder
David Pope
A commercial and operational executive with more than 15 years of leadership experience spanning healthcare, medical technology, energy, and publicly traded companies.
Co-Founder
Dr. John P. Smith, D.O.
A board-certified osteopathic physician and practicing genitourinary medicine specialist with clinical training across family medicine, urology, and men's health.